Clinical validation of NANO-PL: a hydrogel-based formulation of a small molecule...
Clinical validation of NANO-PL: a hydrogel-based formulation of a small molecule for a highly targeted therapy against Glioblastoma Multiforme (GBM)
Glioblastoma (GBM) is considered the highest unmet need in oncology. The average life expectancy of GBM patients is 12-18 months, and the 5-year survival rates remain below 7%. Despite the efforts, the available therapy today coun...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Información proyecto nPL4GBM
Duración del proyecto: 23 meses
Fecha Inicio: 2024-03-13
Fecha Fin: 2026-02-28
Líder del proyecto
TARGTEX SA
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
4M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Glioblastoma (GBM) is considered the highest unmet need in oncology. The average life expectancy of GBM patients is 12-18 months, and the 5-year survival rates remain below 7%. Despite the efforts, the available therapy today counts only with a few (ineffective) approved therapies.
Using a machine learning algorithm, we have discovered a correlation between a small molecule and an unexplored target in GBM. We have developed a hydrogel-based formulation of the molecule with great safety and efficacy in vivo. Our formulation showed 40% long-term survival in a GBM rat model, with complete tumour eradication after a single dose treatment. NANO-PL is a one-time treatment, applied locally during surgery, which is effective even in GBM cells that are resistant to the standard of care or those involved in recurrence. NANO-PL also showed a synergistic efficacy with temozolomide, standard-of-care.
The EIC will enable the clinical validation of NANO-PL, completely unlocking the GBM treatment.